Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma

Season 6 Episode 13  ·  Nov 29, 2021, 07:55 PM
Headliner
Share
Subscribe

Sameek Roychowdhury, MD, PhD, discusses the pivotal phase 2 trial with infigratinib in FGFR-positive cholangiocarcinoma, the safety and efficacy achieved with infigratinib, and the next steps for this agent.

Share
Subscribe
Next
Bleicher and Nardello Talk About Finding the Best Fit for Fellowship in Oncology
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air